Adocia v. Eli Lilly & Company’s $1.39 Billion Trade Secret Arbitration

Covington successfully advised Eli Lilly & Company on the case.

A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies’ prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia’s intellectual property, and while they denied Lilly’s smaller counterclaim, ruled that Lilly is not liable for damages.

Adocia (Euronext Paris: FR0011184241 – ADOC) is a biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides.

Eli Lilly and Company is a global health care leader that discovers, develops, manufactures, and sells pharmaceutical products for humans and animals.

The Covington team was led by Marney L. Cheek (Picture) and also included partners Clara J. Shin and Jeffrey M. Davidson in San Francisco and Megan P. Keane and Miguel López Forastier in Washington, D.C.; associates Jared Frisch and Clovis Trevino in Washington, D.C.; Isaac Chaput, Udit Sood, Dylan Silva, Kanu Song, and Breanna Jones in San Francisco, and Andrew Regan in Palo Alto.

Involved fees earner: Isaac Chaput – Covington & Burling; Marney Cheek – Covington & Burling; Jeffrey Davidson – Covington & Burling; Jared Frisch – Covington & Burling; Breanna Jones – Covington & Burling; Megan Keane – Covington & Burling; Miguel López Forastier – Covington & Burling; Andrew Regan – Covington & Burling; Clara Shin – Covington & Burling; Dylan Silva – Covington & Burling; Kanu Song – Covington & Burling; Udit Sood – Covington & Burling; Clovis Trevino – Covington & Burling;

Law Firms: Covington & Burling;

Clients: Eli Lilly and Company;

Author: Ambrogio Visconti